 |
49 Diseases |  |
64 Trials |
|
64 Trials |  |
670 News |  |
| «1234567891011» |
- | Onureg (azacitidine oral) / BMS
New P2/3 trial: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Mar 16, 2021
P2/3, N=422, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Mar 12, 2021
P1, N=54, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2021 --> Sep 2023
- | Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 26, 2021
P2, N=349, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2021 --> Sep 2023 Trial primary completion date: Feb 2021 --> Mar 2020
- | abiraterone acetate / Generic mfg.
Biomarker, Trial completion date, Trial primary completion date: Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms (clinicaltrials.gov) - Feb 24, 2021
P1, N=20, Active, not recruiting, Sponsor: Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair
Trial primary completion date: Feb 2021 --> Mar 2020 Trial completion date: Nov 2020 --> Jun 2021 | Trial primary completion date: Oct 2020 --> Jun 2021
- | prednisone delayed-release tablet / Generic mfg.
Retrospective data, Journal: Role of imaging in the evaluation of intussusception in adults: a 10-year retrospective study. (Pubmed Central) - Feb 23, 2021
Trial completion date: Nov 2020 --> Jun 2021 | Trial primary completion date: Oct 2020 --> Jun 2021 The increased use of abdominal imaging has shown that a significant proportion of cases of intussusception are idiopathic and resolve spontaneously.
- | Opdivo (nivolumab) / Ono Pharma, BMS
New P3 trial, Combination therapy: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Feb 18, 2021
P3, N=192, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Enrollment change, Trial suspension, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Feb 15, 2021
P2, N=60, Suspended, Sponsor: M.D. Anderson Cancer Center
The increased use of abdominal imaging has shown that a significant proportion of cases of intussusception are idiopathic and resolve spontaneously. N=25 --> 60 | Active, not recruiting --> Suspended
- | Venclexta (venetoclax) / Roche, AbbVie, DS-1594 / Daiichi Sankyo
New P1/2 trial, Combination therapy: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 11, 2021
P1/2, N=122, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion date, Trial primary completion date: P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - Feb 11, 2021
P2, N=53, Recruiting, Sponsor: City of Hope Medical Center
N=25 --> 60 | Active, not recruiting --> Suspended Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment change: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 10, 2021
P2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022 N=60 --> 80
- | Calquence (acalabrutinib) / AstraZeneca
Trial initiation date: Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Feb 10, 2021
P2, N=45, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
N=60 --> 80 Initiation date: Jan 2021 --> Jan 2022
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Feb 9, 2021
P1, N=54, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2021 --> Jan 2022 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2023 --> Sep 2021
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Roche
New P2 trial, Checkpoint inhibition: PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (clinicaltrials.gov) - Feb 8, 2021
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial suspension: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 4, 2021
P2, N=58, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2023 --> Sep 2021 Recruiting --> Suspended
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Talzenna (talazoparib) / Pfizer
New P2 trial: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (clinicaltrials.gov) - Feb 2, 2021
P2, N=70, Not yet recruiting, Sponsor: City of Hope Medical Center
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Trial completion date, Trial primary completion date, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jan 28, 2021
P2, N=25, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
- | Jakafi (ruxolitinib) / Incyte
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 26, 2021
P2, N=12, Completed, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2020 --> Oct 2021 Active, not recruiting --> Completed | N=92 --> 12 | Trial completion date: Jul 2023 --> Jan 2021 | Trial primary completion date: Jul 2023 --> Jan 2021
- || prednisone delayed-release tablet / Generic mfg.
Hola Fran, solo leer las respuestas de la comunidad (medica y no medica) para darse cuenta que NO sirve hacer esto. Yo no quiero "rayos de luz" quiero ciencia y salvar vidas. Y al menos, algun estudio que nos oriente. Ojala se publique pronto y sea positivo, ojala. (Twitter) - Jan 23, 2021
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Trial primary completion date: AHOD1331: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (clinicaltrials.gov) - Jan 12, 2021
P3, N=600, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=92 --> 12 | Trial completion date: Jul 2023 --> Jan 2021 | Trial primary completion date: Jul 2023 --> Jan 2021 Trial primary completion date: Dec 2020 --> Jun 2021
- || Darzalex (daratumumab) / J&J
Enrollment closed, Trial completion date, Trial primary completion date: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma (clinicaltrials.gov) - Jan 11, 2021
P1, N=15, Active, not recruiting, Sponsor: AIDS Malignancy Consortium
Trial primary completion date: Dec 2020 --> Jun 2021 Suspended --> Active, not recruiting | Trial completion date: Jun 2023 --> Aug 2024 | Trial primary completion date: Jun 2021 --> Aug 2022
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 7, 2021
P2, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting | Trial completion date: Jun 2023 --> Aug 2024 | Trial primary completion date: Jun 2021 --> Aug 2022 Trial primary completion date: Jul 2021 --> Jun 2022
- | prednisone delayed-release tablet / Generic mfg.
Cómo rayos??? (Twitter) - Jan 3, 2021
- | prednisone delayed-release tablet / Generic mfg.
Journal: The beginnings of radiology in Malaga. (Pubmed Central) - Dec 18, 2020
In Malaga, the assimilation and progression of the diagnostic and therapeutic use of radiology was slow and affected by peculiarities owing to the social, economic, and cultural circumstances of the period. Influential physicians willing to overcome resistance to advances were able to bring medical practice in Malaga to a level similar to that of other cities.
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Trial primary completion date: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Dec 17, 2020
P3, N=5956, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Influential physicians willing to overcome resistance to advances were able to bring medical practice in Malaga to a level similar to that of other cities. Trial primary completion date: Jun 2021 --> Dec 2022
- || prednisone delayed-release tablet / Generic mfg.
.@nanox_vision ¡La fuente de rayos X digitalizada de Nanox! ¡El primer paso hacia la democratización de las imágenes en todo el mundo! Fuente:@JohnNosta #digitalhealth#healthtech$NNOX#radiology (Twitter) - Dec 11, 2020
- ||| Darzalex (daratumumab) / J&J
Trial suspension: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma (clinicaltrials.gov) - Nov 26, 2020
P1, N=15, Suspended, Sponsor: AIDS Malignancy Consortium
Trial primary completion date: Jun 2021 --> Dec 2022 Recruiting --> Suspended
- || Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment change: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 23, 2020
P1, N=24, Recruiting, Sponsor: University of Washington
Recruiting --> Suspended N=36 --> 24
- | Calquence (acalabrutinib) / AstraZeneca
New P2 trial: Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Nov 12, 2020
P2, N=45, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
- | veliparib (ABT-888) / AbbVie, Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma
Trial completion, PARP Biomarker, Metastases: Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Nov 12, 2020
P2, N=159, Completed, Sponsor: National Cancer Institute (NCI)
N=36 --> 24 Active, not recruiting --> Completed
- || Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date, Metastases: Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer (clinicaltrials.gov) - Nov 5, 2020
P2, N=76, Recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Trial completion date: Mar 2023 --> Jan 2026 | Trial primary completion date: Mar 2022 --> Jan 2024
- ||||| itacitinib (INCB039110) / Incyte
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Oct 28, 2020
P2/3, N=401, Recruiting, Sponsor: Incyte Corporation
Trial completion date: Mar 2023 --> Jan 2026 | Trial primary completion date: Mar 2022 --> Jan 2024 Phase classification: P3 --> P2/3 | N=266 --> 401 | Trial completion date: Oct 2023 --> Feb 2025 | Trial primary completion date: Aug 2023 --> Jan 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (clinicaltrials.gov) - Oct 28, 2020
P3, N=330, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P3 --> P2/3 | N=266 --> 401 | Trial completion date: Oct 2023 --> Feb 2025 | Trial primary completion date: Aug 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Enrollment closed, Enrollment change, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Oct 22, 2020
P2, N=25, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=60 --> 25
- ||| prednisone delayed-release tablet / Generic mfg.
La radioterapia es un tto con rayos (o partículas) de alta energía que destruyen las células cancerosas. Algunas mujeres con cáncer de mama necesitarán radiación, además de otros ttos. (Twitter) - Oct 19, 2020
- ||| prednisone delayed-release tablet / Generic mfg.
No necesariamente. La tomografia es un estudio de rayos X con dosis mas altas, las cuales son captadas por una maguina y pueden generar imagenes de todo el cuerpo. Sirve para ver si el cancer ha avanzado a otros organos. (Twitter) - Oct 19, 2020
- ||| prednisone delayed-release tablet / Generic mfg.
Mamografia 3D -Se usan rayos X para tomar una serie de imágenes del interior de la mama desde ángulos diferentes. Se usa una computadora para crear imágenes tridimensionales de la mama -Puede detectar cancer pequenos que se esconden en mamograma -No disponible en muchos centros. (Twitter) - Oct 18, 2020
- ||||||| itacitinib (INCB039110) / Incyte
Trial completion, Trial completion date, Combination therapy: GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - Oct 14, 2020
P3, N=439, Completed, Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting | N=60 --> 25 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2020
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Oct 12, 2020
P1, N=54, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2020 Trial completion date: Sep 2020 --> Jul 2023 | Trial primary completion date: Sep 2020 --> Jul 2023
- || prednisone delayed-release tablet / Generic mfg.
Como el descubrimiento de la TAC ha suscitado interés os dejo lo mejor q he leído sobre Hounsfield. Merece la pena: está escrito en castellano y por un residente de 2º año de Rayos argentino https://t.co/j2VXCgaDyg (Twitter) - Oct 11, 2020
- ||| prednisone delayed-release tablet / Generic mfg.
Clinical: Neumotórax a tensión. Por el hecho de que existe la rayos X ya esta en una institución, por tanto, el manejo es con sonda endopleural, si fuera manejo prehospitalario, habría que colocar un catéter de descompresión. (Twitter) - Oct 9, 2020
- prednisone delayed-release tablet / Generic mfg.
[VIRTUAL] Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2552;
P4
DR and IR prednisone were comparable in improving fatigue in patients with SLE. Despite no change in daily prednisone dosage from prescribed doses at entry, fatigue significantly improved, implying that one contributor to fatigue in SLE may be differences between prescribed and actual administered doses of prednisone.
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 8, 2020
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Despite no change in daily prednisone dosage from prescribed doses at entry, fatigue significantly improved, implying that one contributor to fatigue in SLE may be differences between prescribed and actual administered doses of prednisone. Trial primary completion date: Nov 2020 --> Nov 2021 | Trial completion date: Nov 2020 --> Nov 2021
- | lenalidomide / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, IO biomarker: Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL) (clinicaltrials.gov) - Oct 7, 2020
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2020 --> Nov 2021 | Trial completion date: Nov 2020 --> Nov 2021 Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2022
- || prednisone delayed-release tablet / Generic mfg.
@DrTedros @antonioguterres HASTA QUE SE "REABRA" LO SUFICIENTE EL AGUJERO DE LA CAPA DE OZONO, PARA DEJAR PASAR RAYOS ULTRAVIOLETA DESINFECTANTES DEL SOL, SE PUEDE INSTALAR ALUMBRADO INTERNO Y PUBLICO CON LAMPARAS DE RAYOS ULTRAVIOLETA CON 222 nN QUE NO AFECTA AL SER HUMANO.. (Twitter) - Sep 27, 2020
- | Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Sep 23, 2020
P2, N=345, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Jun 2022 | Trial primary completion date: Jan 2022 --> Jun 2022 Trial primary completion date: Sep 2020 --> Feb 2021
- prednisone delayed-release tablet / Generic mfg.
[VIRTUAL] Rayos Contra Cancer: Empowering Centers in limited-resource areas through education, training, and new telehealth models (T.J. Eichler Theater, Panel) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_2798;
- prednisone delayed-release tablet / Generic mfg.
[VIRTUAL] Panel 22 - Expanding Radiation Oncology Worldwide: A Review of Non-Profit Organization Initiatives and Panel Discussion on Opportunities for Engagement (T.J. Eichler Theater, Panel) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_2792;
This session will include presentations by RAD-AID, Radiating Hope, Rayos Contra Cancer, iTreatSafey, ICEC, and Chartrounds...Describe established solutions that address common needs and problems in radiotherapy in developing countries. Describe opportunities for volunteerism to improve radiotherapy in developing countries.
- prednisone delayed-release tablet / Generic mfg.
[VIRTUAL] Initial Impact and Operational Response of Radiation Oncology Practices to the COVID-19 Pandemic in the United States, Europe, and Latin America (Science Center, Oral Scientific Sessions) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_2704;
Treatment access policies reflected rapidly published international guidelines to delay treatment for low-risk diagnoses. Patients with higher risk disease continued to receive uninterrupted access to care.
- prednisone delayed-release tablet / Generic mfg.
[VIRTUAL] OpenABC: An Open-Source Active Breathing Control System for Low-Resource Centers (Poster Hall) - Sep 13, 2020 - Abstract #ASTRO2020ASTRO_1060;
We demonstrated feasibility of an open-source accelerometer/gyroscope-based system for active breathing control for motion gating or breath-hold radiation treatments, called OpenABC. Future work will further develop OpenABC to have user friendly GUIs, standardize use protocols and showing proof-of-concept implementation, in collaboration with Rayos Contra Cancer (RCC) and Radiating Hope, in cancer centers in Bolivia that would benefit from motion management in their clinics.
- || prednisone delayed-release tablet / Generic mfg.
Pero el hecho de que por un virus familia y amigos se hayan tenido que separar y mantener distancia me duele, yo por ejemplo pocas veces tengo oportunidad de salir y por ende muchas veces no veo la luz del día pero a veces quiero sentir de vuelta los rayos del Sol en mi cuerpo... (Twitter) - Sep 6, 2020